.
Clinical Pharmacy
Study Course Description
Course Description Statuss:Approved
Course Description Version:8.00
Study Course Accepted:07.08.2023 09:52:00
| Study Course Information | |||||||||
| Course Code: | FKK_030 | LQF level: | Level 7 | ||||||
| Credit Points: | 4.00 | ECTS: | 6.00 | ||||||
| Branch of Science: | Basic Sciences of Medicine, including Pharmacy; Clinical Pharmacy | Target Audience: | Clinical Pharmacy | ||||||
| Study Course Supervisor | |||||||||
| Course Supervisor: | Inga Urtāne | ||||||||
| Study Course Implementer | |||||||||
| Structural Unit: | Department of Pharmaceutical Chemistry | ||||||||
| The Head of Structural Unit: | |||||||||
| Contacts: | Riga, 16 Dzirciema Street, zftk rsu[pnkts]lv, +371 67061547 | ||||||||
| Study Course Planning | |||||||||
| Full-Time - Semester No.1 | |||||||||
| Lectures (count) | 4 | Lecture Length (academic hours) | 3 | Total Contact Hours of Lectures | 12 | ||||
| Classes (count) | 4 | Class Length (academic hours) | 3 | Total Contact Hours of Classes | 12 | ||||
| Total Contact Hours | 24 | ||||||||
| Full-Time - Semester No.2 | |||||||||
| Lectures (count) | 4 | Lecture Length (academic hours) | 3 | Total Contact Hours of Lectures | 12 | ||||
| Classes (count) | 4 | Class Length (academic hours) | 3 | Total Contact Hours of Classes | 12 | ||||
| Total Contact Hours | 24 | ||||||||
| Study course description | |||||||||
| Preliminary Knowledge: | Pharmacology, pharmacotherapy, practical pharmacy and pharmaceutical legislation, social pharmacy and pharmaceuticals, English. | ||||||||
| Objective: | Promote knowledge acquisition and awareness raising on clinical pharmacy and the role of a clinical pharmacist in healthcare. | ||||||||
| Topic Layout (Full-Time) | |||||||||
| No. | Topic | Type of Implementation | Number | Venue | |||||
| 1 | Pharmacy and Clinical Pharmacy – common and different. | Lectures | 0.50 | auditorium | |||||
| Classes | 1.00 | laboratory | |||||||
| 2 | Basic rules of clinical dialogue (situation analysis). | Lectures | 0.50 | auditorium | |||||
| Classes | 1.00 | laboratory | |||||||
| 3 | Clinical trials – methods of obtaining information, processing and presenting results. | Lectures | 0.50 | auditorium | |||||
| Classes | 0.50 | laboratory | |||||||
| 4 | Analysis of research protocol. | Lectures | 0.50 | auditorium | |||||
| Classes | 1.00 | laboratory | |||||||
| 5 | Differences in clinical pharmacokinetics and factors affecting them. | Lectures | 0.50 | auditorium | |||||
| Classes | 0.50 | laboratory | |||||||
| 6 | Pharmacokinetic profile analysis of drug substances (situation tasks). | Lectures | 0.50 | auditorium | |||||
| 7 | Therapeutic drug monitoring – risks and opportunities. | Lectures | 1.00 | auditorium | |||||
| 8 | Therapeutic drug monitoring – risks and opportunities – continued. | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | laboratory | |||||||
| 9 | Analysis of drug prescription cases. | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | laboratory | |||||||
| 10 | Adverse drug reactions – causes, risks, consequences. | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | auditorium | |||||||
| 11 | Clinical case presentations. | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | laboratory | |||||||
| Assessment | |||||||||
| Unaided Work: | Preparation of presentations according to the topics of the course, work with medical databases, calculation of tasks according to the topics of the lectures. It is recommended to fill in the study course survey, evaluating the existing course content and creating proposals for updating the course. | ||||||||
| Assessment Criteria: | The final assessment of the study course consists of the assessment of presentations (50%) and the examination mark (50%). | ||||||||
| Final Examination (Full-Time): | Exam (Written) | ||||||||
| Final Examination (Part-Time): | |||||||||
| Learning Outcomes | |||||||||
| Knowledge: | Upon successful completion of the course, students will have acquired knowledge that will allow to: 1. recognize the scope and tasks of the clinical pharmacist; 2. define and outline the principles for evidence-based drug selection; 3. understand the role of the clinical pharmacist in promoting patient safety; 4. formulate and describe the role and tasks of hospital pharmacy in the healthcare system. | ||||||||
| Skills: | On study course completion students will be able to: 1. identify the areas of activity of the clinical pharmacist; 2. evaluate and explain the role of the clinical pharmacist in the development of a patient safety system; 3. participate in the planning, organization and monitoring of the rational use of funds for the purchase of medicines; 4. participate in the development, maintenance and use of a rational drug information system; 5. participate in the design, implementation and improvement of a system for the detection, analysis and elimination of medication therapy errors. | ||||||||
| Competencies: | 1. As a result of successful completion of the course students will be able to apply the acquired knowledge in clinical pharmacist's work. 2. Provide advice to health professionals based on guidelines, accepted standards, evidence-based medical knowledge. 3. Will be able to participate in the development of health policy oriented towards rational pharmacotherapy, in the definition of directions and goals of development, in the forecasting and planning of its individual stages. 4. Will be able to fill in the study course questionnaire with proposals for updating the course. | ||||||||
| Bibliography | |||||||||
| No. | Reference | ||||||||
| Required Reading | |||||||||
| 1 | Clinical Pharmacy and Therapeutics / edited by Cate Whittlesea and Karen Hodson. 6th edition. [Oxford]: Elsevier, 2019. xiv, 1094 lpp. | ||||||||
| 2 | Haughey, Sharon. Pharmacy OSCES and competency-based assessments / Queen's University, Belfast, Northern Ireland, UK, Roisin O'Hare, BSc, MSc, DPharm, MPSNI(IP), FFRPS, Lead, 2018. | ||||||||
| 3 | Oxford handbook of clinical pharmacy / edited by Philip Wiffen, Marc Mitchell, Melanie Snelling, Nicola Stoner. 3rd edition. Oxford; New York: Oxford University Press, 2017. xvi, 728 lpp. Oxford medical publications. Oxford handbooks. (brošēts). | ||||||||
| Additional Reading | |||||||||
| 1 | Crombie I.K., Davies H.T. What is meta-analysis? Bandolier, 2009 April [online]. | ||||||||
| 2 | Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ, 2003; 327: 557–560. | ||||||||
| 3 | Ebell M., Siwek J., Weiss B.D., et al. Strength of Recommendation Taxonomy (SORT): A Patient-Centered Approach to Grading Evidence in the Medical Literature. Am Fam Physician, 2004; 69:548-556. | ||||||||
| 4 | Guyatt G., Cairns J., Churchill D, et al. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA, 1992; 268:2420-2425 | ||||||||
| 5 | Hemingway P. What is a systematic review? Bandolier, 2009 April [online]. | ||||||||
| 6 | Ioannidis J.P., N.A. Patsopoulos, E.Evangelou. Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 2007; 335: 914–916. | ||||||||
| 7 | Pediatric Medication Errors: Using the National Patient Safety Goals to Protect Patients. The Joint Commission Perspectives on Patient Safety, 2008 June;8(6) | ||||||||
| 8 | Seven steps to patient safety: A guide for NHS staff. National Patient Safety Agency, 2004. | ||||||||
| Other Information Sources | |||||||||
| 1 | Cochrane library | ||||||||
| 2 | Pubmed | ||||||||
| 3 | DynaMed | ||||||||
| 4 | ClinicalKey First Consult | ||||||||
| 5 | Micromedex | ||||||||
